The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib. (PubMed, Clin Lung Cancer) - Oct 1, 2026 - "The TIME classification based on PD-L1 and CD8+TIL statuses, as well as FOXP3+TIL status, may help predict the efficacy of osimertinib in EGFR-mutant NSCLC."
IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • EGFR • FOXP3 • PD-1 • PD-L1
|
|
Akira Sugimoto; Chisato Ohe; Hiroaki Nagamine; Hiroyasu Kaneda; Kazuhiro Yamada; Kazuhisa Asai; Kenichi Kohashi; Masanori Shiohara; Megumi Mizutani; Takako Oka; Tatsuo Kimura; Tetsuya Watanabe; Tomoya Kawaguchi; Yoko Tani; Yoshiya Matsumoto
|